PEC could be a new anticancer therapeutic agent enhancing the treatment responses for human gastric carcinoma with potential impact on the choice of therapy in the case of inhibitors of PI3K, AKT, and mTOR, which is cancer specific. Here, AKT1 is linked to cancer.